Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy

Nicola Fossati, RJ Karnes, M Colicchia, SA Boorjian, A. Bossi, T Seisen, N Di Muzio, C Cozzarini, B Noris Chiorda, C Fiorino, G Gandaglia, P Dell'Oglio, SF Shariat, G Goldner, S Joniau, A Battaglia, K Haustermans, G De Meerleer, V Fonteyne, P OstH Van Poppel, T Wiegel, F Montorsi, A Briganti

Research output: Contribution to journalArticle

Abstract

Background: Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients. Objective: We aimed to identify the optimal candidates for early SRT after RP. Design, setting, and participants: The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received SRT for either prostate-specific antigen (PSA) rising, or PSA persistence after RP that was defined as PSA level ≥0.1 ng/ml at 1 mo after surgery. All patients received local radiation to the prostate and seminal vesicle bed. Outcome measurements and statistical analysis: The primary outcome measured was distant metastasis after SRT. Regression tree analysis was used to develop a risk-stratification tool. Multivariable Cox regression analysis and nonparametric curve fitting methods were used to explore the relationship between PSA level at SRT and the probability of metastasis-free survival at 8 yr. Results and limitations: At a median follow-up of 8.0 yr, 130 patients developed distant metastasis. At multivariable analysis, pre-SRT PSA level was significantly associated with distant metastasis (hazard ratio: 1.01, p <. 0.0001). However, when patients were stratified into five risk groups using regression tree analysis (area under the curve: 85%), early SRT administration provided better metastasis-free survival in three groups only: (1) low risk: undetectable PSA after RP, Gleason score ≤7, and tumour stage ≥pT3b, (2) intermediate risk: undetectable PSA after RP with Gleason score ≥8, (3) high risk: PSA persistence after RP with Gleason score ≤7. Conclusions: We developed an accurate risk stratification tool to facilitate the individualised recommendation for early SRT based on prostate cancer characteristics. Early SRT proved to be beneficial only in selected groups of patients who are more likely to be affected by clinically significant but not yet systemic recurrence at the time of salvage treatment administration. Patient summary: In patients affected by prostate cancer recurrence after radical prostatectomy, the early administration of salvage radiation therapy is beneficial only for selected subgroups of patients. In this study, these groups of patients were identified. In this multi-institutional study, we developed a prognostic tool to assess the risk of distant metastases after early salvage radiation therapy for prostate-specific antigen (PSA) rise after prostatectomy. Five distinct risk groups were identified based on clinical and pathological characteristics. Early salvage radiation therapy administration was noted to be associated with improved cancer control for low-, intermediate-, and high-risk patients. Conversely, very low-risk (undetectable PSA after radical prostatectomy, Gleason score ≤7, and tumour stage ≤pT3a) and very high-risk patients (PSA persistence after radical prostatectomy, and Gleason score ≥8) did not benefit from early salvage treatment. These findings facilitate the identification of optimal candidates for early salvage radiation therapy, and, pending validation, application into clinical practice will help to maximise cancer control while avoiding overtreatment. © 2017 European Association of Urology.
Original languageEnglish
Pages (from-to)436-444
Number of pages9
JournalEuropean Urology
Volume73
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Salvage Therapy
Prostate-Specific Antigen
Prostatectomy
Secondary Prevention
Radiotherapy
Neoplasm Grading
Neoplasm Metastasis
Regression Analysis
Recurrence
Neoplasms
Prostatic Neoplasms
Background Radiation
Survival
Seminal Vesicles

Cite this

Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. / Fossati, Nicola; Karnes, RJ; Colicchia, M; Boorjian, SA; Bossi, A.; Seisen, T; Di Muzio, N; Cozzarini, C; Noris Chiorda, B; Fiorino, C; Gandaglia, G; Dell'Oglio, P; Shariat, SF; Goldner, G; Joniau, S; Battaglia, A; Haustermans, K; De Meerleer, G; Fonteyne, V; Ost, P; Van Poppel, H; Wiegel, T; Montorsi, F; Briganti, A.

In: European Urology, Vol. 73, No. 3, 2018, p. 436-444.

Research output: Contribution to journalArticle

Fossati, N, Karnes, RJ, Colicchia, M, Boorjian, SA, Bossi, A, Seisen, T, Di Muzio, N, Cozzarini, C, Noris Chiorda, B, Fiorino, C, Gandaglia, G, Dell'Oglio, P, Shariat, SF, Goldner, G, Joniau, S, Battaglia, A, Haustermans, K, De Meerleer, G, Fonteyne, V, Ost, P, Van Poppel, H, Wiegel, T, Montorsi, F & Briganti, A 2018, 'Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy', European Urology, vol. 73, no. 3, pp. 436-444. https://doi.org/10.1016/j.eururo.2017.07.026
Fossati, Nicola ; Karnes, RJ ; Colicchia, M ; Boorjian, SA ; Bossi, A. ; Seisen, T ; Di Muzio, N ; Cozzarini, C ; Noris Chiorda, B ; Fiorino, C ; Gandaglia, G ; Dell'Oglio, P ; Shariat, SF ; Goldner, G ; Joniau, S ; Battaglia, A ; Haustermans, K ; De Meerleer, G ; Fonteyne, V ; Ost, P ; Van Poppel, H ; Wiegel, T ; Montorsi, F ; Briganti, A. / Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. In: European Urology. 2018 ; Vol. 73, No. 3. pp. 436-444.
@article{6e5a2c6895a14a4395e65a228e47e1e3,
title = "Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy",
abstract = "Background: Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients. Objective: We aimed to identify the optimal candidates for early SRT after RP. Design, setting, and participants: The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received SRT for either prostate-specific antigen (PSA) rising, or PSA persistence after RP that was defined as PSA level ≥0.1 ng/ml at 1 mo after surgery. All patients received local radiation to the prostate and seminal vesicle bed. Outcome measurements and statistical analysis: The primary outcome measured was distant metastasis after SRT. Regression tree analysis was used to develop a risk-stratification tool. Multivariable Cox regression analysis and nonparametric curve fitting methods were used to explore the relationship between PSA level at SRT and the probability of metastasis-free survival at 8 yr. Results and limitations: At a median follow-up of 8.0 yr, 130 patients developed distant metastasis. At multivariable analysis, pre-SRT PSA level was significantly associated with distant metastasis (hazard ratio: 1.01, p <. 0.0001). However, when patients were stratified into five risk groups using regression tree analysis (area under the curve: 85{\%}), early SRT administration provided better metastasis-free survival in three groups only: (1) low risk: undetectable PSA after RP, Gleason score ≤7, and tumour stage ≥pT3b, (2) intermediate risk: undetectable PSA after RP with Gleason score ≥8, (3) high risk: PSA persistence after RP with Gleason score ≤7. Conclusions: We developed an accurate risk stratification tool to facilitate the individualised recommendation for early SRT based on prostate cancer characteristics. Early SRT proved to be beneficial only in selected groups of patients who are more likely to be affected by clinically significant but not yet systemic recurrence at the time of salvage treatment administration. Patient summary: In patients affected by prostate cancer recurrence after radical prostatectomy, the early administration of salvage radiation therapy is beneficial only for selected subgroups of patients. In this study, these groups of patients were identified. In this multi-institutional study, we developed a prognostic tool to assess the risk of distant metastases after early salvage radiation therapy for prostate-specific antigen (PSA) rise after prostatectomy. Five distinct risk groups were identified based on clinical and pathological characteristics. Early salvage radiation therapy administration was noted to be associated with improved cancer control for low-, intermediate-, and high-risk patients. Conversely, very low-risk (undetectable PSA after radical prostatectomy, Gleason score ≤7, and tumour stage ≤pT3a) and very high-risk patients (PSA persistence after radical prostatectomy, and Gleason score ≥8) did not benefit from early salvage treatment. These findings facilitate the identification of optimal candidates for early salvage radiation therapy, and, pending validation, application into clinical practice will help to maximise cancer control while avoiding overtreatment. {\circledC} 2017 European Association of Urology.",
author = "Nicola Fossati and RJ Karnes and M Colicchia and SA Boorjian and A. Bossi and T Seisen and {Di Muzio}, N and C Cozzarini and {Noris Chiorda}, B and C Fiorino and G Gandaglia and P Dell'Oglio and SF Shariat and G Goldner and S Joniau and A Battaglia and K Haustermans and {De Meerleer}, G and V Fonteyne and P Ost and {Van Poppel}, H and T Wiegel and F Montorsi and A Briganti",
year = "2018",
doi = "10.1016/j.eururo.2017.07.026",
language = "English",
volume = "73",
pages = "436--444",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy

AU - Fossati, Nicola

AU - Karnes, RJ

AU - Colicchia, M

AU - Boorjian, SA

AU - Bossi, A.

AU - Seisen, T

AU - Di Muzio, N

AU - Cozzarini, C

AU - Noris Chiorda, B

AU - Fiorino, C

AU - Gandaglia, G

AU - Dell'Oglio, P

AU - Shariat, SF

AU - Goldner, G

AU - Joniau, S

AU - Battaglia, A

AU - Haustermans, K

AU - De Meerleer, G

AU - Fonteyne, V

AU - Ost, P

AU - Van Poppel, H

AU - Wiegel, T

AU - Montorsi, F

AU - Briganti, A

PY - 2018

Y1 - 2018

N2 - Background: Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients. Objective: We aimed to identify the optimal candidates for early SRT after RP. Design, setting, and participants: The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received SRT for either prostate-specific antigen (PSA) rising, or PSA persistence after RP that was defined as PSA level ≥0.1 ng/ml at 1 mo after surgery. All patients received local radiation to the prostate and seminal vesicle bed. Outcome measurements and statistical analysis: The primary outcome measured was distant metastasis after SRT. Regression tree analysis was used to develop a risk-stratification tool. Multivariable Cox regression analysis and nonparametric curve fitting methods were used to explore the relationship between PSA level at SRT and the probability of metastasis-free survival at 8 yr. Results and limitations: At a median follow-up of 8.0 yr, 130 patients developed distant metastasis. At multivariable analysis, pre-SRT PSA level was significantly associated with distant metastasis (hazard ratio: 1.01, p <. 0.0001). However, when patients were stratified into five risk groups using regression tree analysis (area under the curve: 85%), early SRT administration provided better metastasis-free survival in three groups only: (1) low risk: undetectable PSA after RP, Gleason score ≤7, and tumour stage ≥pT3b, (2) intermediate risk: undetectable PSA after RP with Gleason score ≥8, (3) high risk: PSA persistence after RP with Gleason score ≤7. Conclusions: We developed an accurate risk stratification tool to facilitate the individualised recommendation for early SRT based on prostate cancer characteristics. Early SRT proved to be beneficial only in selected groups of patients who are more likely to be affected by clinically significant but not yet systemic recurrence at the time of salvage treatment administration. Patient summary: In patients affected by prostate cancer recurrence after radical prostatectomy, the early administration of salvage radiation therapy is beneficial only for selected subgroups of patients. In this study, these groups of patients were identified. In this multi-institutional study, we developed a prognostic tool to assess the risk of distant metastases after early salvage radiation therapy for prostate-specific antigen (PSA) rise after prostatectomy. Five distinct risk groups were identified based on clinical and pathological characteristics. Early salvage radiation therapy administration was noted to be associated with improved cancer control for low-, intermediate-, and high-risk patients. Conversely, very low-risk (undetectable PSA after radical prostatectomy, Gleason score ≤7, and tumour stage ≤pT3a) and very high-risk patients (PSA persistence after radical prostatectomy, and Gleason score ≥8) did not benefit from early salvage treatment. These findings facilitate the identification of optimal candidates for early salvage radiation therapy, and, pending validation, application into clinical practice will help to maximise cancer control while avoiding overtreatment. © 2017 European Association of Urology.

AB - Background: Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients. Objective: We aimed to identify the optimal candidates for early SRT after RP. Design, setting, and participants: The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received SRT for either prostate-specific antigen (PSA) rising, or PSA persistence after RP that was defined as PSA level ≥0.1 ng/ml at 1 mo after surgery. All patients received local radiation to the prostate and seminal vesicle bed. Outcome measurements and statistical analysis: The primary outcome measured was distant metastasis after SRT. Regression tree analysis was used to develop a risk-stratification tool. Multivariable Cox regression analysis and nonparametric curve fitting methods were used to explore the relationship between PSA level at SRT and the probability of metastasis-free survival at 8 yr. Results and limitations: At a median follow-up of 8.0 yr, 130 patients developed distant metastasis. At multivariable analysis, pre-SRT PSA level was significantly associated with distant metastasis (hazard ratio: 1.01, p <. 0.0001). However, when patients were stratified into five risk groups using regression tree analysis (area under the curve: 85%), early SRT administration provided better metastasis-free survival in three groups only: (1) low risk: undetectable PSA after RP, Gleason score ≤7, and tumour stage ≥pT3b, (2) intermediate risk: undetectable PSA after RP with Gleason score ≥8, (3) high risk: PSA persistence after RP with Gleason score ≤7. Conclusions: We developed an accurate risk stratification tool to facilitate the individualised recommendation for early SRT based on prostate cancer characteristics. Early SRT proved to be beneficial only in selected groups of patients who are more likely to be affected by clinically significant but not yet systemic recurrence at the time of salvage treatment administration. Patient summary: In patients affected by prostate cancer recurrence after radical prostatectomy, the early administration of salvage radiation therapy is beneficial only for selected subgroups of patients. In this study, these groups of patients were identified. In this multi-institutional study, we developed a prognostic tool to assess the risk of distant metastases after early salvage radiation therapy for prostate-specific antigen (PSA) rise after prostatectomy. Five distinct risk groups were identified based on clinical and pathological characteristics. Early salvage radiation therapy administration was noted to be associated with improved cancer control for low-, intermediate-, and high-risk patients. Conversely, very low-risk (undetectable PSA after radical prostatectomy, Gleason score ≤7, and tumour stage ≤pT3a) and very high-risk patients (PSA persistence after radical prostatectomy, and Gleason score ≥8) did not benefit from early salvage treatment. These findings facilitate the identification of optimal candidates for early salvage radiation therapy, and, pending validation, application into clinical practice will help to maximise cancer control while avoiding overtreatment. © 2017 European Association of Urology.

U2 - 10.1016/j.eururo.2017.07.026

DO - 10.1016/j.eururo.2017.07.026

M3 - Article

VL - 73

SP - 436

EP - 444

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -